A U.S. cannabis company, Curaleaf Holdings Inc., has made a bid to acquire Aurora Cannabis Inc., a firm based in Edmonton. Aurora has set up a special committee to review the unsolicited offer following the announcement by Curaleaf. If successful, the acquisition would result in the formation of a combined cannabis entity operating in 17 countries across Europe, North America, and other global markets.
Curaleaf, based in Stamford, Conn., and listed on the Toronto Stock Exchange, disclosed its intention to pursue the acquisition publicly after unsuccessful private negotiations with Aurora’s leadership. The company stated that despite sending formal letters of intent on June 23 and a subsequent follow-up on July 7 outlining the proposal, Aurora’s board declined to engage in meaningful discussions.
In response, Curaleaf expressed disappointment with Aurora’s lack of engagement, prompting them to take the proposal directly to Aurora’s shareholders. The proposed deal entails offering Aurora shareholders $4 US per share, along with an additional $0.75 US in cash for each Aurora share.
Aurora confirmed receiving the letters from Curaleaf but disputed the claim that they refused to engage with the offer. The Canadian company highlighted that dialogue with Curaleaf’s CEO occurred as recently as July 24, emphasizing a focus on executing its business plan in the short to medium term. Aurora emphasized the formation of a special committee to evaluate the proposal’s alignment with stakeholders’ interests, with no assurance of a finalized agreement at this stage.
While acknowledging Curaleaf’s interest in the acquisition, analysts from TD Cowen cautioned that the current offer undervalues Aurora’s long-term potential. They emphasized Aurora’s strong market position in medical cannabis, diverse product portfolio, financial stability, and ability to navigate international regulations as factors contributing to the company’s sustained value growth over time.
Curaleaf’s CEO highlighted the strategic benefits of merging the companies, citing the synergy between Curaleaf’s global distribution network and Aurora’s established international medical cannabis operations. The combined entities reported over $1.5 billion US in revenue in the past year, with Curaleaf anticipating annual cost synergies exceeding $40 million US from the proposed acquisition. The CEO expressed confidence that the merger would create mutual benefits for shareholders by leveraging a more diversified global platform and tapping into favorable U.S. regulatory trends.